WillItSurvive
Pharma and healthcare groups · United States

Ionis Pharmaceuticals

ionispharma.com ↗

Ionis makes RNA-targeting drugs (antisense) for rare and cardiometabolic disease.

Protection under test
Assessed 30 July 2026 · Evidence as of 30 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 30 July 2026 · Checkable from Sept 22, 2026 · Every call on the record Checkpoint: Zilganersen (Alexander disease) FDA decision, first planned independent neurology launch
The call

Ionis has approved drugs and cash to fund itself, but its next big cardiac bet just failed and rivals already sell competing RNA drugs in the same diseases.

Ionis Pharmaceuticals develops and sells medicines for rare diseases like heart and liver problems caused by genetic issues. The company's drugs have patent protections and FDA approvals that prevent exact copies, but competitors like Arrowhead and Alnylam are attacking the same diseases with different technology approaches, which patents cannot block. The company is losing money each quarter and betting its entire path to profitability on one drug trial called pelacarsen reading out soon, while simultaneously losing market share in a key product called Tryngolza to Arrowhead's competing medicine.

Why
01
AI pressure: None apparent. No AI lab or product is displacing Ionis today; its fights are modality battles against rival RNA drugmakers, not algorithms. Could AI do the core job? Unlikely.
02
Bigger players: Pfizer (Vyndamax) and Alnylam Pharmaceuticals (Amvuttra). Vyndamax already owns ATTR-CM care and Amvuttra is live in the same disease, the market eplontersen just failed to enter. Could a giant copy it? No, they are blocked.
03
What protects it. Approved, patented drugs like Spinraza and Tryngolza plus a Biogen royalty stream give Ionis cash rivals can't easily copy.
What would change this call
Arrowhead's plozasiran FDA submission outcome and sHTG uptake versus Tryngolza by end 2026. Shows whether Ionis is losing its flagship independent-launch drug's market to a rival RNAi therapy.
Pelacarsen HORIZON Lp(a) Phase 3 trial readout. Tests whether Ionis meets the milestone it tied its 2028 cash breakeven target to.
Zilganersen PDUFA decision on September 22 2026. Indicates whether Ionis can successfully launch its first independent neurology drug.
Key numbers
  • Q2 2026 revenue $268M, up 56% YoY (2026-07-29)
  • Q2 2026 net loss $115M (2026-07-29)
  • Cash and investments $2.1B, down from $2.7B (2026-07-29)
Named risks
  • 2028 cash-flow breakeven goal tied to single pelacarsen Lp(a) trial outcome. Severity: high
  • Arrowhead plozasiran FDA submission by end 2026 threatens Tryngolza sHTG market share. Severity: high
  • Securities-fraud investigations opened by multiple law firms after 2026-07-09 trial miss. Severity: medium
  • CSO Frank Bennett retirement effective February 2027 creates R&D leadership transition risk. Severity: low
  • Cash declined from $2.7B to $2.1B in H1 2026 amid continued net losses. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Alnylam Pharmaceuticalslosing toAmvuttra gained ground in ATTR-CM after Ionis's eplontersen trial miss on 2026-07-09
Arrowhead PharmaceuticalscontestingPlozasiran shows comparable sHTG efficacy to Tryngolza; FDA submission expected end of 2026
BridgeBio Pharmalosing toAttruby gained investor favor after Ionis's 2026-07-09 CARDIO-TTRansform miss
Pfizerlosing toVyndamax remains dominant ATTR-CM standard-of-care, benefiting from Ionis's cardiac setback
Questions people ask
Is Ionis Pharmaceuticals in financial trouble?
Not by revenue trends, but cash burn is a real watch-item. Trailing twelve-month revenue reached $1.06 billion, up 47.5 percent year over year as of 2026-03-31, yet the company posted a TTM net loss of $381.39 million and cash fell from $2.7 billion to $1.9 billion in a single quarter ending 2026-03-31. Whether Ionis hits its stated breakeven target by year-end 2028 is a concrete date worth checking as this plays out.
Who are Ionis Pharmaceuticals's biggest competitors?
Alnylam Pharmaceuticals is the closest direct rival, already shipping an approved siRNA drug in ATTR cardiomyopathy where Ionis also competes, and it has gained ground since Ionis's July 2026 trial failure. Venture-backed players Arrowhead, Wave, Avidity, and Dyne also chase overlapping RNA-targeting indications, all part of the same competitive set assessed in July 2026.
Is Ionis Pharmaceuticals at risk from AI?
The AI threat is rated 'building' rather than active: labs like Isomorphic Labs, Insilico Medicine, and Recursion Pharmaceuticals aim to design RNA-targeting molecules faster than Ionis's chemistry platform, but none has an approved oligonucleotide drug yet as of the July 2026 assessment. Ionis's 35 years of layered antisense patents give it a chemistry know-how moat that is harder for AI-driven newcomers to replicate quickly, since patent and regulatory barriers, not just molecule design speed, still govern who can bring a drug to market.
Does Ionis Pharmaceuticals have real protection against competitors copying its drugs?
Yes, its layered antisense patents (35 years of them) combined with FDA exclusivity make displacement difficult for newcomers, as of the July 2026 assessment. This protection is strong enough that large partners like AstraZeneca, Novartis, Biogen, and Roche pay to co-commercialize Ionis's drugs rather than try to replicate the antisense technology themselves.
What should I watch to see if Ionis Pharmaceuticals is turning a corner?
Two dated markers matter: whether TRYNGOLZA's quarterly revenue reaches a run-rate implying $500 million or more annualized by December 2027, and whether Ionis reports positive net cash flow or hits its stated breakeven target by year-end 2028. The next concrete checkpoint is the Q2 2026 earnings report on July 29, 2026, which follows FY2026 revenue guidance raised to $875-900 million as of 2026-04-29.
Timeline
  • 2026-07-29Ionis reports Q2 2026 revenue of $268M and net loss of about $115M
  • 2026-07-28Multiple law firms open securities-fraud investigations after stock drop
  • 2026-07-22Arrowhead's plozasiran shows efficacy comparable to Tryngolza in sHTG
  • 2026-07-14Biogen presents Phase 2 CELIA data for diranersen at AAIC
  • 2026-07-09CARDIO-TTRansform Phase 3 misses primary endpoint; stock drops 20-23%
  • 2026-06-30FDA approves Tryngolza for severe hypertriglyceridemia
  • 2026-04-01Ionis repays $633 million of 0% convertible notes
  • 2024-12-01Tryngolza FDA approved for familial chylomicronemia syndrome
  • 2015-12-01Isis Pharmaceuticals renamed Ionis Pharmaceuticals
  • 1989-01-10Company founded as Isis Pharmaceuticals
Head to head
Alnylam Pharmaceuticals vs Ionis PharmaceuticalsIonis Pharmaceuticals vs Sarepta Therapeutics
Revision history
30 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources